Apollo Hospitals Enterprise delivered exceptional financial results for Q4 FY26, with consolidated net profit surging 36% year-on-year to ₹529 crore and revenue growing 18% to ₹6,605 crore for the quarter ended March. For the full fiscal year 2026, the healthcare major reported consolidated revenue of ₹25,229 crore, up 16% YoY, while net profit jumped 34% to ₹1,942 crore. The robust performance was driven by growth across core businesses including Healthcare Services, Diagnostics, and Retail Health, with healthcare services revenue reaching ₹12,555 crore, up 13% YoY, and healthcare net profit increasing 14% to ₹1,628 crore.
The company's expansion strategy continues to focus on India's long-term healthcare needs, with Prathap C Reddy, Chairman, emphasizing commitment to improving access to high-quality healthcare in Tier 2 and Tier 3 markets. Krishnan Akhileswaran, Group Chief Financial Officer, highlighted that growth during the quarter was supported by improved performance in CONGO-T specialties and growth in high-complexity procedures including lung and heart surgeries. The company aims to add another 1,500 operating beds in the next 12-18 months across key metros, taking total operating beds to 10,000. As of March 31, Apollo Hospitals operated 8,131 beds across the network, with overall occupancy at 68% in Q4 FY26 compared to 67% in the previous year.
Apollo's Board has recommended a final dividend of ₹10 per equity share for FY26. The company's expansion plans remain on track with upcoming hospitals in Hyderabad and Sonarpur, Kolkata, and the group launched four hospitals over the past six months. The proposed demerger of Apollo's pharmacy and digital health businesses is progressing towards a potential listing by Q4 FY27, as stated by Prathap C Reddy. Regarding the West Asia crisis impact on foreign patients, Krishnan Akhileswaran confirmed there has been no adverse impact on patient inflow so far.
The exceptional financial performance positions Apollo Hospitals as a standout performer in the healthcare sector, with the company's strategic focus on underserved markets and expansion projects across key cities driving positive sentiment. The 34% profit growth for FY26 and 16% revenue increase demonstrate the company's ability to capitalize on India's growing healthcare demand while maintaining operational efficiency. The proposed demerger and expansion plans indicate strong confidence in the company's long-term growth prospects across multiple healthcare segments.
